Skip to main content
Retour
ESPR logo

Esperion Therapeutics, Inc.

Qualité des données : 100%
ESPR
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
2,62 €
▲ 0,07 € (2,75%)
Cap. Boursière : 544,72M
Fourchette du Jour
2,47 € 2,68 €
Fourchette 52 Semaines
0,69 € 4,18 €
Volume
4 585 446
Moyenne 50J / 200J
3,18 € / 2,62 €
Clôture Précédente
2,55 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -24,0 0,4
P/B 2,9
ROE % 3,7
Net Margin % -5,6 3,9
Rev Growth 5Y % 50,6 10,0
D/E 0,2

Objectif de Cours des Analystes

Hold
9,00 € +243.5%
P/E Prévisionnel
35,5
BPA Prévisionnel
0,07 €
Croissance BPA (est.)
+0,0%
CA Est.
410 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 1,67 €
1,27 € – 2,07 €
1,1 B 1
FY2029 1,17 €
0,89 € – 1,45 €
880 M 1
FY2028 0,34 €
-0,63 € – 1,17 €
550 M 3

Points Clés

Revenue grew 50,56% annually over 5 years — strong growth
Negative free cash flow of -12,90M
PEG of 0,56 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 29,25%
Capital efficient — spends only 0,05% of revenue on capex
ROIC of 18,37% — excellent capital efficiency

Croissance

Revenue Growth (5Y)
50,56%
Revenue (1Y)21,31%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC18,37%
Net Margin-5,63%
Op. Margin14,95%

Sécurité

Debt / Equity
N/A
Current Ratio0,56
Interest Coverage0,71

Valorisation

P/E Ratio
-24,02
P/B RatioN/A
EV/EBITDA15,34
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 21,31% Revenue Growth (3Y) 86,15%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 50,56% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 403,14M Net Income (TTM) -22,68M
ROE N/A ROA -4,87%
Gross Margin 67,95% Operating Margin 14,95%
Net Margin -5,63% Free Cash Flow (TTM) -12,90M
ROIC 18,37% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,56
Interest Coverage 0,71 Dividend Yield 0,00%
Valuation
P/E Ratio -24,02 P/B Ratio N/A
P/S Ratio 1,35 PEG Ratio 0,56
EV/EBITDA 15,34 Dividend Yield 0,00%
Market Cap 544,72M Enterprise Value 924,87M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 403,14M 332,31M 116,33M 75,48M 78,45M
Net Income -22,68M -51,75M -209,25M -233,66M -269,11M
EPS (Diluted) -0,11 -0,28 -2,03 -4,33 -11,03
Gross Profit 273,91M 263,71M 73,07M 48,51M 64,23M
Operating Income 60,27M 54,40M -155,56M -179,50M -226,73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 465,89M 343,82M 205,80M 247,94M 381,59M
Total Liabilities 767,85M 732,54M 660,79M 571,72M 578,53M
Shareholders' Equity -301,97M -388,72M -454,99M -323,78M -196,94M
Total Debt 548,00M 591,21M 540,95M 260,95M 260,20M
Cash & Equivalents 167,85M 144,76M 82,25M 124,78M 208,89M
Current Assets 167,85M 338,00M 201,07M 246,68M 328,97M
Current Liabilities 300,81M 246,23M 156,22M 92,31M 73,35M